Adaptive Biotechnologies ADPT Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Business | ||||||
| Immune Medicine Business | $59.7M-7.6% | $64.64M+4.0% | $62.16M+83.2% | $33.94M+3.1% | $32.9M-1.6% | |
| Mrd Business | $235.71M+11.0% | $212.33M+11.4% | $190.6M+11.3% | $171.28M+9.4% | $156.62M+7.6% | |
| Adjusted Ebitda by Business | ||||||
| Mrd Business | $31.44M+107% | $15.19M+949% | -$1.79M+88.0% | -$14.87M+47.0% | -$28.08M+31.9% | |
| Research And Development Expense by Business | ||||||
| Immune Medicine Business | $55.31M-1.0% | $55.86M-1.9% | $56.96M-0.4% | $57.21M+0.6% | $56.88M-4.7% | |
| Mrd Business | $35.09M+0.2% | $35.03M-0.5% | $35.19M-0.7% | $35.43M-4.2% | $36.98M-9.2% | |
| Revenue by Product | ||||||
| Collaboration Revenue | $37.68M-8.7% | $41.28M-7.8% | $44.78M+208% | $14.55M+17.6% | $12.36M-8.1% | |
| Regulatory Milestone Revenue | $24M+23.1% | $19.5M+18.2% | $16.5M+10.0% | $15M+20.0% | $12.5M0.0% | |
| Service And Licensing Revenue | $21.3M-8.8% | $23.36M+3.8% | $22.51M+3.9% | $21.67M+4.1% | $20.82M+4.2% | |
| Service | $211.71M+9.8% | $192.83M+10.8% | $174.1M+11.4% | $156.28M+8.4% | $144.12M+8.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Adaptive Biotechnologies break its business down?
- Adaptive Biotechnologies (ADPT) reports revenue by business across 2 parts — Immune Medicine Business and Mrd Business. Each is extracted from the segment footnotes and tracked over time.
- Where does Adaptive Biotechnologies's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Adaptive Biotechnologies's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.